Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Óðîëîãèÿ è àíäðîëîãèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #31  
Ñòàðûé 22.10.2002, 06:07
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äà ñàéò äàâíî íå îáíîâëÿëñÿ, ïî÷åìó - íå çíàþ, ëè÷íî íå çíàêîì, äà è ïîäêèíóë åãî, ÷òî áû Âû ëèøíèé ðàç ïîóïðàæíÿëèñü….
Ïîëíîòå èãðàòüñÿ, Âëàäèìèð ßêîâëåâè÷. Ðàç óæ Âû ññûëàåòåñü íà ÷òî íèáóäü, òî óæ íàäîáíî çíàòü çà÷åì. "Ïîóïðàæíÿòüñÿ" âåäü ìîæíî è íà äðóãèõ ðåñóðñàõ, äà òîëüêî îò ýòîãî îáñóæäàåìûé âîïðîñ ÿñíåå íå ñòàíîâèòñÿ.

Äà è Íåìåöêèå, Èòàëüÿíñêèå, òåì áîëåå Êóáèíñêèå ñòàíäàðòû ÿ íå îáÿçàí ïðè ñåáå äåðæàòü.
À Âàñ îá ýòîì è íå ïðîñèëè è ðå÷ü áûëà íå î òîì âîîáùå (Âû ÷åãî ïðåòâîðÿåòåñü, ÷òî íå ïîíèìàåòå î ÷åì Âàñ ñïðàøèâàþò?). À ÷òî â óêàçàííûõ Âàìè ñòðàíàõ ÎÒ âõîäèò â ÑÒÀÍÄÀÐÒÛ ëå÷åíèÿ ê.ë. çàáîëåâàíèé? Âû ìîæåòå ýòî óòâåðæäàòü??? Òàê íå íàäî ïîìíèòü âñå íàèçóñòü, ïðîñòî åñëè ýòî òàê òî ñêàæèòå - äà ÎÒ âõîäèò â òàêîé òî ñòðàíå, â ñòàíäàðòû ëå÷åíèÿ òàêèõ òî çàáîëåâàíèé (êàê ôàêò). Èëè íåò íå âõîäèò, âîò è âñå. À òî Âû êàê òî âñå âîêðóã äà îêîëî. Òèïè÷íûé "àëüòåðíàòèâíûé" ïîäõîä.

À òî óæ êàê Âû èçâèâàëèñü, îòðèöàëè ( è ñåé÷àñ áóäåòå îòðèöàòü), íå çàìå÷àëè, ïåðåäåðãèâàëè, ñîãëàøàëèñü, à ïîòîì îïÿòü îòêàçûâàëèñü, êîãäà ïðèâîäèëèñü ìàòåðèàëû (èõ ìàòåðèàëû!), ÷òî ðûëüöå îðòîäîêñàëüíîé ìåäèöèíû â ïóøêó.
Âû çíàåòå, ÿ â êîòîðûé ðàç óáåäèëñÿ, ÷òî Âû î÷åíü ñêëîííû íàâåøèâàòü ÿðëûêè. ß ïðîñòî ãîòîâ âñåãäà ïðèçíàòüñÿ åñëè íå ïðàâ è åñëè óçíàþ ÷òî òî äëÿ ñåáÿ íîâîå (â îòëè÷èå îò Âàñ, êñòàòè). ×òî äî ïðèâîäèìûõ Âàìè ìàòåðèàëîâ, òî íè â îäíîì èç íèõ (êðîìå áðåäà îò òîâ. Æóêîâñêîãî è ò.ï. ðîññèéñêèõ äåÿòåëåé) íå ãîâîðèëîñü, ÷òî äå ïðîáëåìû ñåãîäíÿøíåé "îðòîäîêñàëüíîé" ìåäèöèíû ñâÿçàíû ñ ïîðî÷íîñòüþ ìåäèêàìåíòîçíîé òåðàïèè êàê òàêîâîé. Ãîâîðèëîñü â îñíîâíîì î ÷åëîâå÷åñêîì ôàêòîðå êàê ïðè÷èíå îøèáîê è ïîðî÷íîñòè íåêîòîðûõ êîìïîíåíòîâ ñèñòåìû îêàçàíèÿ ìåäïîìîùè, åå ôèíàíñèðîâàíèÿ è ò.ï.

Àõ äà ôèíàíñèðîâàòü ñòàëè õóæå, äåíåã íå õâàòàåò, êàê æå òîãäà ãîðåìû÷íûå «àëüòåðíàòèâùèêè» âûæèâàþò – îíè âåäü âîîáùå íè öåíòà, íè ïî êàêèì êàíàëàì, êðîìå êàê îò áîëüíîãî íå ïîëó÷àþò?
Âî-ïåðâûõ ýòî íåïðàâäà. Ñåãîäíÿ àêóïóíêòóðà è òðàâîëå÷åíèå, à òàêæå ãîìåîïàòèÿ è äèåòîòåðàïèÿ îïëà÷èâàþòñÿ ìíîãèìè ñòðàõêîìïàíèÿìè â ÑØÀ.
Âî-âòîðûõ àëüòåðíàòèâùèêè íå äåëàþò ïîãîäó â çäðàâîîõðàíåíèè è íè÷åãî âîîáùå â íåì íå îïðåäåëÿþò íè â îäíîé öèâèëèçîâàííîé (è äàæå íå öèâèëèçîâàííîé) ñòðàíå. Ê íèì îáðàùàþòñÿ èëè îò îò÷àÿíèÿ, èëè îò íåäîèíôîðìèðîâàííîéñòè èëè îò æåëàíèÿ "äî êó÷è" ñäåëàòü äëÿ ëå÷åíèÿ ñâîåé áîëåçíè âñå âîçìîæíîå (êàê àìåðèêàíöû). Àìåðèêàíñêèé ïîòðåáèòåëü ñàìûé áîãàòûé â ìèðå è ìîæåò ñåáå ïîçâîëèòü ïëàòèòü çà âåùè åìó ïî÷òè íå íóæíûå, òàê "just to have some fun" or "may be I need it to" or "May be it works and you never know. Why not to try it?". Ñåêòîð àëüòåðíàòèâíîé ìåäèöèíû íå äîñòèãàåò â ÑØÀ è $ 15 ìëðä. â ãîä, â òî âðåìÿ êàê îáîðîò â èíäóñòðèè çäðàâîîõðàíåíèÿ ïåðåâàëèë çà $ 1 òðëí. ãîäîâûõ, íå ñ÷èòàÿ îáîðîòîâ ôàðìáèçíåñà. Âñå ïîïûòêè âíèìàòåëüíîãî è õîðîøî ôèíàíñèðîâàííîãî èçó÷åíèÿ âîçìîæíîñòåé àëüòåðíàòèâíîé ìåäèöèíû ñî âðåìåí Êëèíòîíà (ñåðåäèíà 90-õ) ïðèâåëè ïîêà òîëüêî ê íåêîòîðûì äîñòàòî÷íî áàíàëüíûì "îòêðûòèÿì" â îáëàñòè ïèòàíèÿ, â ò.÷. ïðè ðàçëè÷íûõ çàáîëåâàíèÿõ, äà íåêîòîðûõ ìàëîçíà÷èìûõ óñïåõàõ â ïðèìåíåíèè òðàâ, àêóïóíêòóðû è ãîìåîïàòèè. ÍÈÊÀÊÈÕ ÑÅÍÑÀÖÈÉ (ÂÐÎÄÅ ÒÅÕ, ÊÎÒÎÐÛÅ ÂÛ ÁÎÄÐÎ È ÁÅÇÄÎÊÀÇÀÒÅËÜÍÎ ÏÐÈÏÈÑÛÂÀÅÒÅ ÎÇÎÍÎÒÅÐÀÏÈÈ) ÏÎÊÀ ÍÅ ÏÐÎÈÇÎØËÎ È ÍÅ ÎÏÈÑÀÍÎ. Òàê ÷òî äîñòîéíîé àëüòåðíàòèâû ñåãîäíÿøíåé ìåäèöèíû ñî âñåìè åå áåçóñëîâíî èìåþùèìè ìåñòî íåäîñòàòêàìè íåò. È óæ åñëè ëþäåé ñåðüåçíî ïðèïèðàåò, ïîäàâëÿþùåå áîëüøèíñòâî èíôîðìèðîâàííîãî è ïñèõè÷åñêè âìåíÿåìîãî íàñåëåíèÿ èùåò ïîìîùü ïðîôåññèîíàëüíîãî âðà÷à, à àëüòåðíàòèâùèêè èäóò òàê íà çàêóñêó è äî êó÷è ïî ïðèíöèïó - ÿ ñäåëàë äëÿ ñåáÿ (êîãî-òî) âñå, ÷òî ìîã.
Òî ëè äåëî êîíãðåññ ÑØÀ ñïåöèàëüíî çàèíòåðåñîâàëñÿ, ïî÷åìó âäðóã âñå áîëüøå àìåðèêàíöåâ îáðàùàþòñÿ ê àëüòåðíàòèâíîé ìåäèöèíå, õîòÿ èõ ñïåöèàëüíî âñå âðåìÿ ïðåäóïðåæäàþò
Ê âûøåïðèâåäåííûì êîììåíòàðèÿì ìîæíî òîëüêî äîáàâèòü, ÷òî àìåðèêàíöåâ è äðóãèõ ïðåäóïðåæäàþò î âðåäå êóðåíèÿ, íî îíè êóðÿò ñåáå è êóðÿò (îñîáåííî äåòè è ìîëîäåæü). ×åëîâåêó ñâîéñòâåííî ïðîáîâàòü âñå, ÷òî ïðåäëàãàåòñÿ è îòíþäü íå òîëüêî ïîòîìó, ÷òî ýòî êàê òî äëÿ íåãî îäíîçíà÷íî ïîëåçíî, íî è ïî äðóãèì ÷èñòî ýìîöèîíàëüíûì è èððàöèîíàëüíûì ïðè÷èíàì, âåðîâàíèÿì, íàèòèÿì è çàáëóæäåíèÿì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #32  
Ñòàðûé 22.10.2002, 12:11
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Àëåêñåé Âèêòîðîâè÷!
Îäíà èç îñíîâíûõ ïðè÷èí, ÷òî ÿ íå âèæó ñìûñëà ïðîäîëæàòü ýòó äèñêóññèþ, òî ÷òî Âû â ëþáîì ñëó÷àå áóäåòå èíòåðïðåòèðîâàòü èíôîðìàöèþ, êîòîðàÿ ïðèâîäèòñÿ, òàê êàê Âàì õî÷åòñÿ (âûãîäíî).
Íåêîòîðûå îôèöèàëüíî ïðèâåäåííûå â ÑØÀ äàííûå ïðîñòî âîïèþò, à Âû îïÿòü « î áðåäå îò òîâ. Æóêîâñêîãî». Ìíå, ÷òî îïÿòü èõ öèòèðîâàòü? ×åãî òîëüêî ñòîÿò äâà äîêëàäà 2000ã - ÂÎÇ î íåïîìåðíî áîëüøîì è îïàñíîì ïðèìåíåíèè àíòèáèîòèêîâ, è ÌÊÊÍ ïðè ÎÎÍ î ÷ðåçìåðíîì ïîòðåáëåíèåì ëåêàðñòâ â ïðîìûøëåííî ðàçâèòîì ìèðå. À óæ ýòè îðãàíèçàöèè áåç îñîáîé íóæäû îáèæàòü ôàðìèíäóñòðèþ íå áóäóò. Èëè äàííûå ïðèâåäåííûå â äîêëàäå ÖÐÓ, â òîì æå ãîäó, òîæå ñ ïîäà÷è Æóêîâñêîãî íàïèñàíû? Ïîíèìàþ, Âàñ áîëüøå ãðåþò ñîîáùåíèÿ ðàçíûõ ìåä. àññîöèàöèé, êðîâíî çàèíòåðåñîâàííûõ õîðîøî âûãëÿäåòü. Äà è ñðåäè íèõ óæå äîñòàòî÷íî ïðåäñòàâèòåëåé, êîòîðûå íà÷èíàþò ñòûäèòüñÿ ïðÿòàòü ãîëîâó â ïåñîê.
Äàæå öèôðû, êîòîðûå óæå ïðèâîäèëèñü, Âû â äâà ðàçà, íî óìåíüøèòå.
Ãàðâàðäñêèå ìåäèêè ðåøèëè ïðîâåðèòü àëüòåðíàòèâíûå ìåòîäû 16 ìàÿ 2001
Ìåäèêè Ãàðâàðäñêîãî óíèâåðñèòåòà ðåøèëè ïðîòåñòèðîâàòü â ëàáîðàòîðíûõ óñëîâèÿõ îñíîâíûå âèäû àëüòåðíàòèâíîé ìåäèöèíû. Àìåðèêàíöû âñå ÷àùå ïðèáåãàþò ê óñëóãàì "àëüòåðíàòèâíûõ" ìåäèêîâ: òàê, òîëüêî çà ïîñëåäíèé ãîä îíè ïîòðàòèëè íà ïîñåùåíèå öåëèòåëåé íåòðàäèöèîííîãî òîëêà îêîëî 30 ìèëëèàðäîâ äîëëàðîâ. Îñíîâíîé çàäà÷åé ó÷åíûõ ñòàíåò ïîèñê ïóòåé èíòåãðàöèè ìåòîäîâ è òåõíèê êëàññè÷åñêîé ìåäèöèíû è òåõ ìåäèöèíñêèõ ïðàêòèê, êîòîðûå äî íåäàâíåãî âðåìåíè âûçûâàëè ó ìåäèêîâ äîñòàòî÷íî ïðåíåáðåæèòåëüíîå îòíîøåíèå. Èñòî÷íèê: MIGnews

Àëåêñåé Âèêòîðîâè÷! Åäèíñòâåííàÿ öåëü Âàøèõ ïîñòîâ – óòâåðäèòü äëÿ ñåáÿ è îêðóæàþùèõ ìûñëü, ÷òî ïðèìåíÿåìûå Âàìè ìåòîäèêè ñàìûå, åñëè íå åäèíñòâåííî ïðàâèëüíûå.
Åù¸ ðàç, äàâàéòå ïîïðîùàåìñÿ. Âåäü áîëüøå î òîì, ÷òî Çàéöåâ èç ñåáÿ ïðåäñòàâëÿåò, ÷åì Âû óæå ñîîáùèëè, âñå ðàâíî íè ÿ, íè îêðóæàþùèå íå óçíàþò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #33  
Ñòàðûé 22.10.2002, 22:10
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âëàäèìèð ßêîâëåâè÷,
ß âñå æå äóìàë, ÷òî Âû êîãäà íèäóëü äîãàäàåòåñü, ÷òî ÿ íå ñòàâëþ ñâîåé öåëüþ ïåðåóáåäèòü Çàéöåâà. Íà Âàøåì ïðèìåðå, êàê ýòî íå öèíè÷íî çâó÷èò, î÷åíü õîðîøî ïîêàçûâàòü âñþ àáñóðäíîñòü ïîäõîäà è îòíîøåíèÿ ê àëüòåðíàòèâíîé ìåäèöèíå â ðîññèéñêîì âàðèàíòå. Âåäü ãëàâíîå, ÷òî îòëè÷àåò âìåíÿåìûõ àìåðèêàíñêèõ àëüòåðíàòèâùèêîâ (ÿ çíàþ çàâåäóþùåãî êàôåäðîé àëüòåðíàòèâíîé è êîìïëèìåíòàðíîé ìåäèöèíû îäíîãî èç Íüþ-Éîðêñêèõ óíèâåðñèòåòñêèõ ãîñïèòàëåé, îí âûõîäåö èç ñåìåéíûõ âðà÷åé) îò Âàñ, òàê ýòî ïîëíîå ïðèñóòñòâèå êðèòèêè ê òîìó, ÷òî îíè äåëàþò, à òàêæå èõ ñòðåìëåíèå ïîäâåðãíóòü ïðîâåðêå ýôôåêòèâíîñòü ïðàêòèêóåìûõ èìè ìåòîäîâ â ðàìêàõ îáùåïðèíÿòûõ êëèíè÷åñêèõ èñïûòàíèé.  îòëè÷èå îò Âàñ îíè ïðåêðàñíî çíàþò êëèíè÷åñêóþ ýïèäåìèîëîãèþ (÷àñòü áîðäîâñêîãî ýêçàìåíà) è õîðîøî çíàêîìû ñ áèîñòàòèñòèêîé. Ó Âàñ æå ÷òî íè ññûëêà íà êàêèå òî ðàáîòû ïî ÎÒ, òî ïåðë àáñîëþòíî áåçäîêàçàòåëüíûõ. à ïîðîé è ïðîñòî áåçãðàìîòíûõ è áåññìûññëåííûõ óòâåðæäåíèé.

Íåêîòîðûå îôèöèàëüíî ïðèâåäåííûå â ÑØÀ äàííûå ïðîñòî âîïèþò
Äà, îíè âîïèþò î ÷åì óãîäíî òîëüêî íå î òóïèêîâîñòè ëåêàðñòâåííîé òåðàïèè è óæ òåì áîëåå íå î íåêèõ ïðåèìóùåñòâàõ ìàëîïîíÿòíûõ "ñèñòåìíûõ ïîäõîäîâ" (ýòè ïðåëåñòè ìîæíî íàéòè òîëüêî ó òîâ. Æóêîâñêîãî).

×åãî òîëüêî ñòîÿò äâà äîêëàäà 2000ã - ÂÎÇ î íåïîìåðíî áîëüøîì è îïàñíîì ïðèìåíåíèè àíòèáèîòèêîâ
È ÷òî èç ýòîãî ñëåäóåò? ×òî àíòèáèîòèêè íàäî îòìåíèòü? À ÷òî òîãäà âìåñòî íèõ? Îçîí? Çàðÿæåííàÿ âîäèöà? Êòî åùå ÷òî ïðåäëîæèò? À Âû âîò Âëàäèìèð ßêîâëåâè÷, îõàèâàÿ àíòèáèîòèêè, óäîñóæèëèñü ïðèâåñòè õîòü îäíî ñðàâíèòåëüíîå êîíòðîëèðóåìîå èññëåäîâàíèå ÎÒ ïðîòèâ àíòèáèîòèêîâ? Íå óäîñóæèëèñü âåäü! Òîãäà î ÷åì Âû. Äà ìû âñå ãîðåìû÷íûå çíàåì î íåäîñòàòêàõ àíòèáèîòèêîòåðàïèè. Íî ìû çíàåì è òîì. ÷òî 8 èç 10 ðîññèéñêèõ è íå ìåíåå 4 èç 10 àìåðèêàíñêèõ âðà÷åé òîëêîì íå çíàþò ñîâðåìåííóþ àíòèáèîòèêîòåðàïèþ. Íó òàê ýòî ÷åëîâå÷åñêèé ôàêòîð, íå áîëåå òîãî. Íàäî ïðîñòî âûó÷èòü óðîêè.

è ÌÊÊÍ ïðè ÎÎÍ î ÷ðåçìåðíîì ïîòðåáëåíèåì ëåêàðñòâ â ïðîìûøëåííî ðàçâèòîì ìèðå
À ÷òî ÷ðåçìåðíîñòü óïîòðåáëåíèÿ è áåñïîëåçíîñòü óïîòðåáëåíèÿ ýòî îäíî è òî æå?

Ìåäèêè Ãàðâàðäñêîãî óíèâåðñèòåòà ðåøèëè
ïðîòåñòèðîâàòü â ëàáîðàòîðíûõ óñëîâèÿõ îñíîâíûå âèäû àëüòåðíàòèâíîé ìåäèöèíû.

Âîò ñðàçó âèäíî, ÷òî Âû ÷åëîâåê "ëàáîðàòîðíûé". Íó ïî÷èòàéòå Âû ÷òî íèáóäü ïî êëèíè÷åñêîé ýïèäåìèîëîãèè íàêîíåö. Òàì âàì íà ïàëüöàõ è ïîãðåìóøêàõ îáúÿñíÿò, ÷òî ëàáîðàòîðíûå òåñòèðîâàíèÿ è çíàíèå ïîòåíöèàëüíîãî âîçäåéñòâèÿ ìåòîäà ëå÷åíèÿ íà èçâåñòíûå ôàêòîðû ýòèîïàòîãåíåçà íåäîñòàòî÷íû äëÿ ïðåäñêàçàíèÿ èëè êîíñòàòèðîâàíèÿ ýôôåêòèâíîñòè ìåòîäà ëå÷åíèÿ. Âî-ïåðâûõ èñõîä áîëåçíè çàâèñèò íå òîëüêî îò ôàêòîðîâ ñàìîãî îðãàíèçìà, íî è îò âíåøíåé ñðåäû (êëèìàò. ñîöèàëüíûå óñëîâèÿ, ïèòàíèå è ò.ï.). Âî âòîðûõ ìû íå îáëàäàåì àáñîëþòíî èñ÷åðïûâàþùèì çíàíèåì î âñåõ ìåõàíèçìàõ ýòèîïàòîãåíåçâ è äàëåêî íå âñå ìîæåì ìîäåëèðîâàòü â ëàáîðàòîðèè.

òàê, òîëüêî çà ïîñëåäíèé ãîä îíè ïîòðàòèëè íà ïîñåùåíèå öåëèòåëåé íåòðàäèöèîííîãî òîëêà îêîëî 30 ìèëëèàðäîâ äîëëàðîâ
Ðàñòåò áëàãîñîñòîÿíèå àìåðèêàíñêîãî íàðîäà, äà è äåíåã èì äåâàòü íåêóäà. ß ïðîñòî ïðèâåë íàâåðíîå áîëåå ñòàðûå äàííûå. Íî êàê íè êðóòè 30 ìëðä. è 1 òðèëëèîí âåùè àáñîëþòíî ðàçíûå.

Îñíîâíîé çàäà÷åé ó÷åíûõ ñòàíåò ïîèñê ïóòåé èíòåãðàöèè ìåòîäîâ è òåõíèê êëàññè÷åñêîé ìåäèöèíû è òåõ ìåäèöèíñêèõ ïðàêòèê, êîòîðûå äî íåäàâíåãî âðåìåíè âûçûâàëè ó ìåäèêîâ äîñòàòî÷íî ïðåíåáðåæèòåëüíîå îòíîøåíèå.
Ïîñìîòðèì ÷åãî îíè íàéäóò. Ïîêà çà ïîñëåäíèå 5 ëåò êðàéíå ìàëî óáåäèòåëüíîãî.

Åäèíñòâåííàÿ öåëü Âàøèõ ïîñòîâ – óòâåðäèòü äëÿ ñåáÿ è îêðóæàþùèõ ìûñëü, ÷òî ïðèìåíÿåìûå Âàìè ìåòîäèêè ñàìûå, åñëè íå åäèíñòâåííî ïðàâèëüíûå.
Ýòî äî ìåíÿ óæå óòâåðäèëè è äîêàçàëè. Íå óòâåðæäåíî è íå äîêàçàíî òî. ÷òî ïðåäëàãàåòå Âû. Âàì äàæå íå ïîä ñèëó âñïîìíèòü äà è ïðîñòî çíàòü íå âõîäèò ëè ÎÒ â ñòàíäàðòû ëå÷åíèÿ ê.ë. çàáîëåâàíèé ÷åëîâåêà. Âàøå óïîðíîå çàìàë÷èâàíèå ýòîãî âîïðîñà åùå ðàç äîêàçûâàåò ÷òî íå âõîäèò, à çíà÷èò íå ýôôåêòèâíàÿ â äîñòàòî÷íîé äëÿ ýòîãî ñòåïåíè.

Åù¸ ðàç, äàâàéòå ïîïðîùàåìñÿ.
Äà íåò ïðîáëåì, äàâàéòå. Òîëüêî åñëè ÿ ãäå íèáóäü áóäó âñòðå÷àòü âàøè ïðåäëîæåíèÿ ïîïîëüçîâàòü õðîíè÷åñêèé ïðîñòàòèò èëè òðèõîìîíàäû îçîí÷èêîì. îñòàâëÿþ çà ñîáîé ïðàâî äàâàòü ñîîòâåòñòâóþùóþ îöåíêó áåçäîêàçàòåëüíûì âûñêàçûâàíèåì è ìàëî ÷åì îáîñíîâàííûì ðåêîìåíäàöèÿì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #34  
Ñòàðûé 23.10.2002, 10:05
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Âîò è ëàäóøêè, ÿ òåïåðü õîòü çíàþ ñëîâà çàêëèíàíèÿ äëÿ «âûçîâà» äîêòîðà Æèâîâà, åñëè ñòàíåò ìó÷èòåëüíî áîëüíî çà åãî îòñóòñòâèå.
P.S. Àëåêñåé Âèêòîðîâè÷! Êàêîé æå â Âàñ ïîëèòèê óìåð! Ñ Âàøåé-òî íàñòîé÷èâîñòüþ è ìåòîäèêîé äîâîäèòü äî ìàññ ñâîå ìèðîâîççðåíèå! Ãäå ïåðåôðàçèðóåòå, «óñèëèòå» ñêàçàííîå îïïîíåíòîì, ãäå «íå çàìåòåòå» íåâûãîäíûå äåòàëè è ãëàâíîå áèòü è áèòü â îäíó òî÷êó, êàê â ïîâòîðÿþùåéñÿ ðåêëàìå.
Íåñìîòðÿ íà âåñü Âàø ïàôîñ, ìì ìàëåíüêèå íþàíñû Âû ðàç çà ðàçîì ñòàðàåòåñü óïóñòèòü. Íó õîòÿ áû ïî÷åìó, åñëè áåç ò.í. «äîêàçàòåëüíîé» ìåäèöèíû â Àìåðèêå ñåé÷àñ è âäîõíóòü âðà÷ó íåëüçÿ, ëåòàëüíîñòü ó íèõ îò èíôåêöèîííûõ çàáîëåâàíèé ñ 1980 ïî 2000ã. óâåëè÷èëàñü â äâà ðàçà? Äà, äà ýòî èç òîãî ñàìîãî äîêëàäà ÖÐÓ. À ðîñò, â òîì ÷èñëå, ñ ëåòàëüíûìè èñõîäàìè ëåêàðñòâåííûõ çàáîëåâàíèé?
È ïîòîì, ãäå æå ýòî ÿ, ÷òî îò ìåäèêàìåíòîçíîé òåðàïèè íàäî òàê ñðàçó âçÿòü è îòêàçàòüñÿ? Èëè, àíòèáèîòèêè îòìåíèòü? Ìîæåò, ïîêàæåòå. Ñ òàêèì æå óñïåõîì, ñëîâà, ÷òî â ðàöèîíå ïèòàíèÿ íå äîëæíî äîìèíèðîâàòü ìó÷íîå è ñëàäêîå, ìîæíî èíòåðïðåòèðîâàòü çà ïðèçûâ çà îòìåíó òàêèõ ïðîäóêòîâ. ß âåäü óæå, êàæåòñÿ, ñîîáùàë, ÷òî íèêîãäà äî òîãî ñîñòîÿíèÿ íå íàïèâàþñü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #35  
Ñòàðûé 04.11.2002, 01:54
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
×òî-òî çàêëèíàíèå (äèñêóññèÿ «îçîíîòåðàïèÿ íà Êóáå») íå ñðàáàòûâàåò. Ìîæåò ïîðÿäîê ñëîâ ïåðåïóòàë?
Îòâåòèòü ñ öèòèðîâàíèåì
  #36  
Ñòàðûé 09.11.2002, 20:32
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íó õîòÿ áû ïî÷åìó, åñëè áåç ò.í. «äîêàçàòåëüíîé» ìåäèöèíû â Àìåðèêå ñåé÷àñ è âäîõíóòü âðà÷ó íåëüçÿ, ëåòàëüíîñòü ó íèõ îò èíôåêöèîííûõ çàáîëåâàíèé ñ 1980 ïî 2000ã. óâåëè÷èëàñü â äâà ðàçà? Äà, äà ýòî èç òîãî ñàìîãî äîêëàäà ÖÐÓ.
Ñîèçâîëüòå óòî÷íèòü, Âëàäèìèð ßêîâëåâè÷, çà ñ÷åò êàêèõ èíô. çàáîëåâàíèé îòìå÷àëñÿ ýòîò ðîñò? Íåïëîõî áûëî áû âèäåòü è ññûëêó íà îðèãèíàë.
Îòâåòèòü ñ öèòèðîâàíèåì
  #37  
Ñòàðûé 09.11.2002, 21:21
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Àëåêñåé Âèêòîðîâè÷!
ß æå åãî óæå ïðèâîäèë â íàøåé ñ Âàìè äèñêóññèè, è íå òàê äàâíî. Ïðàâäà, à â êðàòêîì èçëîæåíèè. Âû ïðåäëàãàåòå ìíå çàíÿòüñÿ äîáû÷åé îðèãèíàëà?
Ìîãó ñîñëàòüñÿ è äðóãîé áîëåå ðàííèé èñòî÷íèê è áåç ññûëîê íà óâåëè÷åíèå ðåçèñòåíòíîñòè ê àíòèáèîòèêàì. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #38  
Ñòàðûé 09.11.2002, 21:39
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âî ïåðâûõ ýòà ññûëêà íå ðàáîòàåò. Âî âòîðûõ åùå ðàç: "çà ñ÷åò êàêèõ èíô. çàáîëåâàíèé îòìå÷àëñÿ ýòîò ðîñò?"
Îòâåòèòü ñ öèòèðîâàíèåì
  #39  
Ñòàðûé 09.11.2002, 22:35
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
ÐÌÆ, Òîì 3 ¹ 12, 1996


ÍÎÂÎÑÒÈ NEWS
ÄÈÍÀÌÈÊÀ ÑÌÅÐÒÍÎÑÒÈ ÎÒ ÈÍÔÅÊÖÈÎÍÍÛÕ ÁÎËÅÇÍÅÉ Â ÑØÀ
Èçáàâëåíèå îò èíôåêöèîííûõ áîëåçíåé âñå åùå îñòàåòñÿ íàèâíîé ìå÷òîé ÷åëîâå÷åñòâà. Íåñìîòðÿ íà âñå óñèëèÿ íàó÷íîé è ïðàêòè÷åñêîé ìåäèöèíû, èíôåêöèè (çà ðåäêèì èñêëþ÷åíèåì) íå òîëüêî íå èñ÷åçàþò, íî è óìíîæàþòñÿ, à ìíîãèå, èñ÷åçíóâ, ïîÿâëÿþòñÿ âíîâü.  ÑØÀ, íåñìîòðÿ íà ïðåäñêàçàííîå óìåíüøåíèå ÷àñòîòû èíôåêöèé, íè÷åãî ïîäîáíîãî íå ïðîèçîøëî.  1993 ã. âîâðåìÿ íåðàñïîçíàííûé Hantavirus âûçâàë âñïûøêó ðåñïèðàòîðíûõ çàáîëåâàíèé íà þãî-çàïàäå. Ïàðàçèò Cryptosporidium, ïðîíèêøèé â ñèñòåìó îáùåñòâåííîãî âîäîçàáîðà Ìèëóîêè, âûçâàë 400 000 ñëó÷àåâ äèàðåè, ïðè÷åì áîëåå 4000 áîëüíûõ áûëè ãîñïèòàëèçèðîâàíû (1994 ã.). Äðóãèì ñòðàíàì òîæå åñòü ÷åì "ïîõâàñòàòüñÿ". Íåäàâíèé âñïëåñê ãåìîððàãè÷åñêîé ëèõîðàäêè Ýáîëà â Çàèðå óíåñ æèçíè 79% çàáîëåâøèõ. Èç-çà âñïûøêè ÷óìû â Èíäèè â 1994 ã.ñòàíîâèòñÿ àêòóàëüíûì âîïðîñ î âîçìîæíîì çàâîçå åå â ÑØÀ.
Âñå ýòè ôàêòû íàïîìèíàþò î âàæíîñòè è ïîòåíöèàëüíîé èçìåí÷èâîñòè èíôåêöèîííûõ çàáîëåâàíèé.
Àâòîðû ñòàâèëè öåëü èçó÷èòü äèíàìèêó èíôåêöèîííûõ áîëåçíåé â ÑØÀ, èñïîëüçóÿ ÌÊÁ-9 è äàííûå Íàöèîíàëüíîãî öåíòðà ñòàòèñòèêè çäîðîâüÿ î ìíîãîïðè÷èííûõ ñìåðòÿõ â ïåðèîä 1980 - 1992 ãã.
Îäíàêî ÌÊÁ-9, ïîìèìî ðóáðèêè èíôåêöèîííûõ áîëåçíåé (001 139), ñäåðæèò ñâåäåíèÿ î ìíîæåñòâå çàáîëåâàíèé, êîòîðûå, áóäó÷è èíôåêöèîííûìè ñ òî÷êè çðåíèÿ ýòèîëîãèè, ïîïàëè â äðóãèå ðàçäåëû êëàññèôèêàöèè. Íàïðèìåð, ýíäîêàðäèò ïîïàäàåò â ðóáðèêó ñåðäå÷íî-ñîñóäèñòûõ çàáîëåâàíèé (êîä 421), âîñïàëåíèå ñðåäíåãî óõà - â ðàçäåë áîëåçíåé óõà (382.2), à ïíåâìîêîêêîâûé ìåíèíãèò êëàññèôèöèðóåòñÿ êàê çàáîëåâàíèå ÖÍÑ (êîä.320.1) è ò.ä. Ïîýòîìó àâòîðû â ñâîåì èññëåäîâàíèè îáúåäèíèëè âñå ðàçäåëû ÌÊÁ-9, êàñàþùèåñÿ èíôåêöèîííûõ áîëåçíåé, ÷òîáû èìåòü áîëåå îáúåêòèâíóþ êàðòèíó.  íèõ âîøëè: òóáåðêóëåç, áàêòåðèàëüíûå ìåíèíãèòû, ñåïòèöåìèÿ, ÂÈ×/ÑÏÈÄ, ãåïàòîáèëèàðíûå áîëåçíè, âûáîðî÷íî ïåðèíàòàëüíûå èíôåêöèè, ìèêîçû, èíôåêöèè ñåðäöà, âûáîðî÷íî èíôåêöèè äûõàòåëüíûõ ïóòåé è æåëóäî÷íî-êèøå÷íîãî òðàêòà, èíôåêöèè ïî÷åê è ìî÷åâûõ ïóòåé.
Áûëè ïîëó÷åíû ñëåäóþùèå ðåçóëüòàòû.  ïåðèîä 1980 - 1992 ãã. ñìåðòíîñòü â ðåçóëüòàòå èíôåêöèîííûõ çàáîëåâàíèé â ÑØÀ óâåëè÷èëàñü íà 58%, ñ ïîïðàâêîé íà âîçðàñò - íà 39%. Åå ðîñò â ãðóïïå ëèö ñòàðøå 65 ëåò ñîñòàâèë 25%, à â âîçðàñòíîé ãðóïïå îò 25 äî 44 ëåò îíà âîçðîñëà â 6,3 ðàçà. Ñìåðòíîñòü îò çàáîëåâàíèé ðåñïèðàòîðíîãî òðàêòà óâåëè÷èëèñü íà 20%.
Ñìåðòíîñòü îò ÑÏÈÄà ñ íóëÿ âûðîñëà ê 1992 ã. äî 13 íà 100 000, è â ÑØÀ ÑÏÈÄ ñòàë ãëàâíîé ïðè÷èíîé ñìåðòè ìîëîäûõ ëþäåé â âîçðàñòå îò 25 äî 44 ëåò. Ñìåðòíîñòü îò ñåïòèöåìèè óâåëè÷èëàñü íà 83%.
Ýòè äàííûå âíîâü çàñòàâëÿþò çàäóìàòüñÿ íàä âîïðîñàìè ïðîôèëàêòèêè èíôåêöèîííûõ çàáîëåâàíèé.
Ëèòåðàòóðà:
JAMA 1996:275:189-93.
Îòâåòèòü ñ öèòèðîâàíèåì
  #40  
Ñòàðûé 10.11.2002, 22:46
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Exclamation Òàê ïî÷åìó æå âñå òàêè âûðîñëà ñìåðòíîñòü îò èíôåêöèîííûõ çàáîëåâàíèé (ÈÇ) â ÑØÀ?

Âëàäèìèð ßêîâëåâè÷,
Òî, ÷òî Âû íå ÷èòàåòå îðèãèíàëîâ, à âñå áîëüøå óâëåêàåòåñü âîëüíûìè ïåðåâîäàìè è ÑÌÈøíûìè îòêðâåíèÿìè äåëàåò î÷åíü ëåãêèì äåëîì ïðîäåìîñòðèðîâàòü òåíäåíöèîçíîñòü è îäíîáîêîñòü Âàøèõ àðãóìåíòàöèé, íà êîòîðîé ñòðîèòñÿ Âàøà îçîíî-âñåîðãàíèçìåííî-ðåçèñòåíòíàÿ èäåîëîãèÿ. ß õî÷ó ïðîäåìîíñòðèðîâàòü ïóáëèêå áîëåå ïîçäíþþ ñòàòüþ èç JAMA, ÷òîáû ïîäòâåðäèòü ýòîò ìîé òåçèñ.

JAMA 1999 Jan 6;281(1):61-6
Trends in infectious disease mortality in the United States during the 20th century.

Armstrong GL, Conn LA, Pinner RW.

National Foundation for Infectious Diseases, Centers for Disease Control and Prevention, National Center for Infectious Diseases, Atlanta, GA, USA.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

CONTEXT: Recent increases in infectious disease mortality and concern about emerging infections warrant an examination of longer-term trends. OBJECTIVE: To describe trends in infectious disease mortality in the United States during the 20th century. DESIGN AND SETTING: Descriptive study of infectious disease
mortality in the United States. Deaths due to infectious diseases from 1900 to 1996 were tallied by using mortality tables. Trends in age-specific infectious disease mortality were examined by using age-specific death rates for 9 common infectious causes of death. SUBJECTS: Persons who died in the United States
between 1900 and 1996. MAIN OUTCOME MEASURES: Crude and age-adjusted mortality rates. RESULTS: Infectious disease mortality declined during the first 8 decades of the 20th century from 797 deaths per 100000 in 1900 to 36 deaths per 100000
in 1980. From 1981 to 1995, the mortality rate increased to a peak of 63 deaths per 100000 in 1995 and declined to 59 deaths per 100000 in 1996. The decline was interrupted by a sharp spike in mortality caused by the 1918 influenza epidemic. From 1938 to 1952, the decline was particularly rapid, with mortality decreasing
8.2% per year. Pneumonia and influenza were responsible for the largest number of infectious disease deaths throughout the century. Tuberculosis caused almost as many deaths as pneumonia and influenza early in the century, but tuberculosis
mortality dropped off sharply after 1945. Infectious disease mortality increased in the 1980s and early 1990s in persons aged 25 years and older and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-year-olds and, to a lesser degree, to increases in pneumonia and influenza deaths among persons aged 65 years and older. There was considerable year-to-year variability in infectious disease mortality, especially for the youngest and oldest age groups. CONCLUSIONS: Although most of the 20th century has been marked by declining infectious disease mortality, substantial
year-to-year variation as well as recent increases emphasize the dynamic nature of infectious diseases and the need for preparedness to address them.
Öèòàòà:
JAMA 1999 Jan 6;281(1):61-6
Èòàê äëÿ òåõ ó êîãî åñòü ñëîæíîñòè ñ àíãëèéñêìè ðàçáåðåì íåêîòîðûå âàæíûå ïîëîæåíèÿ ýòîé ñòàòüè.

Èòàê ïåðâîå. Infectious disease mortality declined during the first 8 decades of the 20th century from 797 deaths per 100000 in 1900 to 36 deaths per 100000
Ýòî ñíèæåíèå ñìåðòíîñòè îò èíôåêöèîííûõ çàáîëåâàíèé â ÑØÀ çà ïåðâûå 80 ëåò 20-ãî âåêà áîëåå ÷åì â 20 ðàç ÷òî áëàãîäÿðÿ îçîíîòåðàïèè èëè ãîìåîïàòèè ñëó÷èëîñü??? Èëè ìîæåò îíè òàì åùå êàêèå ìåòîäû âñåñòîðîííåîãî óêðåïëåíèÿ ðåçèñòåíñòíîñòè ðàçâñåãî îðãàíèçìà ïðèìåíÿëè? Äà íåò, ïðîñòî ïîÿâèëèñü àíòèáèîòèêè è âàêöèíû. Âñå ãðàçäî ìåíåå ðîìàíòè÷íî.

From 1938 to 1952, the decline was particularly rapid, with mortality decreasing 8.2% per year.
èòàê îñîáåííî îùóòèìîå ñíèæåíèå ñìåðòíîñòè îò ÈÇ ñîâïàëî ñ ïîÿâëåíèåì è ïåðâûì îïûòîì ïðèìåíåíèÿ àíòèáèîòèêîâ (íå îçîíîòåðàïèè, ïðîøó çàìåòèòü).

À âîò è ñàìîå ãëàâíîå äëÿ Âàñ è ïî Âàøåé ïðîñüáå, Âëàäèìèð ßêîâëåâè÷:
Infectious disease mortality increased in the 1980s and early 1990s in persons aged 25 years and older and was mainly due to the emergence of the acquired immunodeficiency syndrome (AIDS) in 25- to 64-year-olds and, to a lesser degree, to increases in pneumonia and influenza deaths among persons aged 65 years and older.
Óâåëè÷åíèå ñìåðòíîñòè îò ÈÇ â 80-õ è äî íà÷àëà 90-õ ó ìîëîäûõ, êàê ïîêàçàëè èññëåäîâàòåëè, ñâÿçàíî â îñíîâíîì ñî ÑÏÈÄÎÌ. Ñêàæèòå, êòî âèíîâàò â òîì, ÷òî ñîâðåìåííàÿ ìåäèöèíà åùå íå ïîáåäèëà ÑÏÈÄ? Ïîðî÷íîñòü åå "÷ðåçìåðíî ìåäèêàìåíòîçíîãî" ðàçâèòèÿ? Èçáûòî÷íàÿ è íèêîìó íå íóäæíàÿ äîêàçàòåëüíîñòü? À íåò! Îçîí÷èêîì åùå âèäàòü íèêîìó â ãîëîâó íå ïðèøëî ÑÏÈÄåö òî ïîïîëüçîâàòü! Âîò îíà ñìåðòíîñòü òî ñðàçó áû è ñíèêëà ó ìîëîäûõ ëþäåé.
À êòî âèíîâàò â òîì, ÷òî íàñåëåíèå â ÑØÀ ñòðåìèòåëüíî ñòàðååò? ß äóìàþ îïÿòü æå ðàñïðîêëÿòàÿ äîêàçàòåëüùèíà âèíîâàòà. Íå äàåò îíà èì ñïîêîéíî ïîìèðàòü êàê ðîññèéñêèì ìóæèêàì íå äîæèâ è äî 60. Âîò îíè èìó÷àþòñÿ äî 75-80 ëåò è ïíåâìîíèè è äîáàâëþ îò ñåáÿ èíôåêöèè ìî÷åâûõ ïóòåé ÷àùå ïîäõâàòûâàþò, ìðóò îò íèõ ïåðèîäè÷åñêè. Ñòàðèêè, ÷òî ñ íèõ âçÿòü. Îçîíèòü èõ íàäî íà Êóáó îòïðàâëÿòü, âñåõ ïîãîëîâíî! à îíè ýìáàðãî ñ íåé ââåëè, ïîíèìàø! Ýõ, è âïðàâäó IQ ó ýòèõ àìåðèêàøåê íèçêîâàò áóäåò. Íå âåäàþò îíè ñâîåãî îçîíîâîãî ñ÷àñòüÿ íà îñòðîâå ñâîáîäû.

Íî åñëè áûòü ñåðüåçíûì. òî â ÑØÀ èìåþòñÿ äåéñòâèòåëüíî îáúåêòèâíûå ïðè÷èíû ðîñòà ÈÇ:
1. ÂÈ×-èíôåêöèÿ.
2. Ñòàðåíèå íàñåëåíèÿ.
3. Ðîñò èììèãðàöèè èç ñëàáîðàçâèòûõ ñòðàí.
4. Ïðîáëåìà àíòèáèîòèêîðåçèñòåíòíîñòè.
5. Ïðîáëåìà ïîïóëÿöèîííîãî êîíòðîëÿ çà èíôåêöèîííîé çàáîëåâàåìîñòüþ èç-çà âûñîêîé ìèãðàöèè íàñåëåíèÿ.
Åñòü è äðóãèå ïðîáëåìû. Íî íèãäå â äîñòóïíûõ ìíå èñòî÷íèêàõ ÿ íå âèäåë ìíåíèé î ïîðî÷íîñòè ðàçâèòèÿ ìåäèöèíû â ñòîðîíó äîêàçàòåëüíîñòè è "ìåäèêàìåíòîçíîñòè" êàê ïðè÷èíó ðîñòà ñìåðòíîñòè îò ÈÇ. Êàêèå ïóòè êîíòðîëÿ çà ýòèìè ïðè÷èíàìè ìîæíî îáñóæäàòü. Èìåþòñÿ ñôîðìóëèðîâàííûå ïîäõîäû. Îäíàêî, îïÿòü æå, îíè íå ïîäðàçóìåâàþò íåêîåãî àáñòðàêòíîãî ïîäúåìà ñòîëü æå àáñòðàêòíîé ðåçèñòåíòíîñòè îðãàíèçìà. Îíè ïîäðàçóìåâàþò êîíêðåòíûå ìåðû âîçäåéñòâèÿ íà èçâåñòíûå ïðè÷èíû ñ ïðåäñêàçóåìûì (îòíîñèòåëüíî êîíå÷íî) ðåçóëüòàòîì.  ÷àñòíîñòè äëÿ áîðüáû ñ àíòèáèîòèêîðåçèñòåíòíîñòüþ ïðåäëàãàåòñÿ ñîêðàòèòü áåññìûñëëåííîå è èððàöèîíàëüíîå íàçíà÷åíèå ÀÁ è ðàçðàáîòàòü ìåðû ïðîôèëàêòèêè ÈÁ íà ïðèíöèïàëüíî íîâîé îñíîâå (êàêî ïîêà íå ÿñíî), à òàêæå ñèíòåçèðîâàòü íîâûå è åùå áîëåå ýôôåêòèâíûå ïðåïàðàòû. Ýòî áîëüøàÿ ïðîáëåìà è åñëè åå íå ðåøèòü, ìû ìîæåì âåðíóòüñÿ ê ñìåðòíîñòè îò ÀÁ äîàíòèáèîòèêîâîé ýðû. Î÷åíü îáíàäåæèâàþøùèå íîâîñòè ïîñòóïàþò èç ëàáîðàòîðèé ìîëåêóëÿðíîé ãåíåòèêè. Îòêðûòû ãåíû, êîäèðóþùèå àíòèáèîòèêîðåçèñòåíòíîñòü ó èíäèâèäà. Very promising news!

Êñòàòè, Âëàäèìèð ßêîâëåâè÷, óñïåõè äîêàçàòåëüíîé ìåäèöèíû â îáëàñòè áîðüáû ñ ðàêîì ïðîñòàòû ïðèâåëè çà ïîñëåäíèå 15 ëåò ê ñíèæåíèþ ñìåðòíîñòè îò íåãî íà 20% (äàííûå ñ ïîñëåäíåãî ñúåçäà Àìåð. óðîë. àññîöèàöèè). È íèêòî ðåçèñòåíòíîñòü íå ïîâûøàë (õîòåëè áû íàâåðíîå, íî âíà÷àëå íàäî çíàòü ÷òî è êîãäà íàäî êîíêðåòíî ïîâûøàòü, à ÷òî ïîíèæàòü, ÷òîáû ÷òî-òî öåëåñîîáðàçíî è öåëåíàïðàâëåííî óëó÷øèòü). Ïðîñòî âíåäðèëè â ñòðàíå ñêðèíèíã è ðàííþþ äèàãíîñòèêó ðàêà ïðîñòàòû è èçëå÷èâàþùèå ìåòîäû òåðàïèè ðàííèõ ñòàäèé ÐÏ (ðàäèêàëüíàÿ ïðîñòàòýêòîìèÿ, ëê÷åâàÿ òåðàïèÿ). Õëàìèäèé èç ïðîñòàòû íèêòî íå ãîíÿë, ò.ê. íèêòî èõ òàì íå âèäåë.
Ñ îçîíïðèâåòîì!

Îòâåòèòü ñ öèòèðîâàíèåì
  #41  
Ñòàðûé 10.11.2002, 23:01
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
À ýòî ñîâðåìåííûå òåíäåíöèè â òåðàïèè ñåïñèñà. Ìîæåò êîíå÷íî æå îçîí è îáëàäàåò ñðàçó âñåìè íèæåèçëîæåííûìè ñâîéñòâàìè èñïûòûâàåìûõ ïðåïàðàòîâ. Íî êòî ýòî äîêàçàë???

Ann Pharmacother 2002 Apr;36(4):648-54

New and emerging therapies for sepsis.

Healy DP.

College of Pharmacy, University of Cincinnati, and Shriners Hospitals for Children, PO Box 670004, Cincinnati, OH 45267-0004, USA. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

OBJECTIVE: To review the recent advances related to the pathophysiology of sepsis and the rationale for recombinant human-activated protein C (drotrecogin alfa) and other antisepsis agents currently in Phase III trials. DATA SOURCES: A
MEDLINE (1990-December 2001) search was performed to identify pertinent literature on the pathophysiology of sepsis and treatment strategies. The search was supplemented with AdisInsight (Adis International) using the search terms sepsis, severe sepsis, or septic shock combined with agents in Phase II or higher clinical development. Abstracts presented at infectious diseases and critical care meetings were also reviewed. STUDY SELECTION AND DATA EXTRACTION: Clinical efficacy studies were selected for drotrecogin alfa and other Phase III investigational agents. DATA SYNTHESIS: Our current understanding of the
pathophysiology of sepsis underscores the contribution of increased coagulation and diminished fibrinolytic activity working in conjunction with an excessive and dysregulated inflammatory response. The loss of homeostatic balance among these systems results in a systemic inflammatory response with generalized
coagulopathy, microvascular thrombosis, and, ultimately, acute organ failure and death. As a result of these advances, several compounds are now in various phases of development. A recombinant human form of endogenous activated protein
C (drotrecogin alfa) was recently approved by the Food and Drug Administration for severe sepsis in adults who have a high risk of death. It possesses anticoagulant, profibrinolytic, and antiinflammatory properties. Other compounds currently in Phase III trials include tissue-factor pathway inhibitor, tumor-necrosis factor antibody fragment, platelet-activating factor acetylhydrolase, antithrombin III, and pyridoxylated hemoglobin polyoxyethylene. CONCLUSIONS: With the recent approval of drotrecogin alfa, there is renewed optimism that we can effectively reduce sepsis-associated mortality.

Publication Types: Review
Review, Tutorial

PMID: 11918516 [PubMed - indexed for MEDLINE]

Äà, ïðåäâèäÿ Âàøè íàïàäêè ïî ïîâîäó òîãî, ÷òî ÿ îòðèöàþ ñóùåñòâîâàíèå íåñïåöèôè÷åñêîé è ñïåöèôè÷åñêîé ðåçèñòåíòíîñòè, çàìå÷ó - ÍÅÒ ÍÅ ÎÒÐÈÖÀÞ ÍÈ Â ÊÎÅÌ ÑËÓ×ÀÅ!!! ß òîëüêî ïûòàþñü Âàì âñå âðåìÿ âòîëêîâàòü, ÷òî ïðè êàæäîì êîíêðåòíîì çàáîëåâàíèè íàäîáíî çíàòü êàêîå çíà÷åíèå ýòà ñàìàÿ ðåçèñòåíòíîñòü èìååò? Êàêèå åå ïàðàìåòðû íàèáîëåå âàæíû? Êàê è ÷åì íà íèõ íàäî âîçäåéñòâîâàòü, ÷òîáû ïîëó÷èòü æåëàåìûé ðåçóëüòàò? Íó à ïîòîì. ïîäðîáíî èçó÷èâ òåîðèþ âîïðîñà ïåðåéòè ê "îòâðàòèòåëüíûì" ðàíäîìèçèðîâàííûì è äâîéíûì ñëåïûì, ÷òîáû è íà ïðàêòèêå ïîäòâåðäèòü, ÷òî âñå â æèçíè äåéñòâèòåëüíî òàê, êàê ìû ïðåäïîëàãàåì. Ïðîñòî êàê äåòñêàÿ ïóñòûøêà (ïëàöåáî)!


Îòâåòèòü ñ öèòèðîâàíèåì
  #42  
Ñòàðûé 11.11.2002, 20:03
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
×åñòíî ãîâîðÿ, íå áûëî æåëàíèÿ îòâå÷àòü íà î÷åðåäíîé äåìàãîãè÷åñêèé ïîñò, íî âåäü ä-ð Æèâîâ íå ñî ìíîé äèñêóòèðóåò, îí ê îáùåñòâåííîñòè îáðàùàåòñÿ.
Àëåêñåé Âèêòîðîâè÷!
Âû ïîïðîñèëè, òî÷íåå ïîòðåáîâàëè, ÷òîáû Âàì ïðåäîñòàâèë ññûëêó, è ãäå Âû îïÿòü îáíàðóæèëè ïðîèñêè ÑÌÈ? Ïåðåâîä èç JAMA â ÐÌÆ? È ïðè÷åì òóò «îçîí÷èê», êîòîðûì ïðîñòî ïåñòðèò Âàøå ñîîáùåíèå? Îí, ÷òî ëè âèíîâàò âî âñåõ áåäàõ àìåðèêàíñêîé ìåäèöèíû?
Äîïóñòèì íåòó îçîíà, Àëåêñåé Âèêòîðîâè÷, íåòó. Òóò ìû, ñ Ãàëèíîé Àôàíàñüåâíîé ñîãëàñîâàëè, ÷òî òàêîãî ãàçà, âîîáùå, â ïðèðîäå íå ñóùåñòâóåò. È ÷òî, â ýòîì ñëó÷àå, ïðîäîëæèì ðîñò ëåêàðñòâ íà äóøó íàñåëåíèÿ?
Äî 80 ãîäà â ÑØÀ îòìå÷àëîñü íåóêëîííîå ñíèæåíèå ñìåðòíîñòè îò èíôåêöèîííûõ çàáîëåâàíèé. È âäðóã êðèâàÿ ðåçêî çàãíóëàñü â äðóãóþ ñòîðîíó. ×òî æå ñëó÷èëîñü? ÑÏÈÄ âíîñèò ñâîþ ñóùåñòâåííóþ ëåïòó, â ïðîòèâíîì ñëó÷àå, ñêîðîñòü ðîñòà ëåòàëüíîñòè áûëà áû âîîáùå âûøå âñÿêîãî ïîíèìàíèÿ. Íî, à äðóãèå èíôåêöèîííûå çàáîëåâàíèÿ? Ïî÷åìó, Âû, Àëåêñåé Âèêòîðîâè÷, ïåðåâîäÿ àáçàö èç ïðèâåäåííîé Âàìè ñòàòüè (äëÿ òåõ, êîãî åñòü ñëîæíîñòè ñ àíãëèéñêèì) ñòûäëèâî îáðûâàåò åãî ïîñåðåäèíå? Ó ìîëîäûõ îñíîâíàÿ ïðè÷èíà ðåçêîãî ñêà÷êà ñìåðòíîñòè - ÑÏÈÄ, ýòî, ê ñëîâó, ñëåäóåò è èç òîé ñòàòüè, êîòîðóþ ïðèâîäèë ÿ. Íî îò ïíåâìîíèè ñìåðòíîñòü âîçðîñëà èëè ñíèçèëàñü? À îò çàáîëåâàíèé ðåñïèðàòîðíîãî òðàêòà, à îò ñåïñèñà? È âåäü ðîñò ñìåðòíîñòè ïðè ýòèõ çàáîëåâàíèé, òîæå íå íà åäèíèöû ïðîöåíòîâ.
Òàê ÷òî æå ïðîèçîøëî. Ñòàðåíèå íàñåëåíèÿ, ìèãðàöèÿ – ïðîñòèòå, äåòñêèé ëåïåò, ÷òî äî 80 ãîäà íàñåëåíèå íåóêëîííî ìîëîäåëî èëè â ýòè ãîäû âäðóã îòêðûëè âñå ãðàíèöû äëÿ ëàòèíîàìåðèêàíöåâ? Åäèíñòâåííîå, ÷òî îòëè÷àåò ýòî âðåìÿ - óêëîí íà àáñîëþòíóþ «ñõåìèçàöèþ» ëå÷åíèÿ, ïîÿâëåíèå âñåâîçìîæíûõ «çîëîòûõ ñòàíäàðòîâ», íàïèñàííûõ ïðè àêòèâíîì ó÷àñòèè ôàðìèíäóñòðèè, è êàê ñëåäñòâèå, ðîñò ïðîèçâîäñòâà è óïîòðåáëåíèÿ ëåêàðñòâ. Ïðè÷åì, ïðè ñâîåé ïðèâåðæåííîñòè ê ìåäèêàìåíòàì, âðà÷è íå îñòàíàâëèâàþòñÿ íà äîñòèãíóòîì.
Âîò, ÷òî êàêóþ ñòàòèñòèêó îíè ïðèâîäÿò î ñåáå ñàìè

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


American Public Health Association
January 1, 1999
Policy Number 9908: Addressing the Problem of Bacterial Resistance to Antimicrobial Agents and the Need for Surveillance
The American Public Health Association,
Recognizing the rapid increase in antibiotic resistance in the United States and worldwide1 and understanding the complex nature of this problem, including the selective pressure of overuse and misuse of antibiotics in human medicine, the use of subtherapeutic levels of antibiotics in animal feeds, and the rapid global spread of resistant bacteria;2 and
Acknowledging that in the United States, 190 million daily doses of antibiotics are ordered in hospitals with twenty-five to forty-five percent being unnecessary, 145 million courses of antibiotics are prescribed with twenty to fifty percent being unnecessary, and four million pounds of antimicrobials are used therapeutically in animals (and 16 million pounds are used as growth promoters) with forty to eighty percent being unnecessary;3 and
Being aware of bacterial resistance to all available antibiotics;4 and
Recognizing that prescriptions are written for upper respiratory tract infections to satisfy patients' demands,5 although the antibiotics have little or no benefit;6 and
Being aware of the decrease in antibiotic use following educational intervention involving both health professionals and patients;7,8 and
Acknowledging the need for local surveillance because of geographic variation in resistance patterns,9 the inadequacies of the current surveillance systems for antibiotic resistance,10 and that only $55,400 of the total $74 million total dollars for surveillance was available for antimicrobial resistance;11 and
Acknowledging that the restriction of antibiotic use resulted in decrease in the resistance level in certain organisms;12 and
Recognizing the increase in societal costs because of infections caused by bacteria resistant to antibiotics as indicated by the assessment of the Office of Technology Assessment (citing that antibiotic resistant bacteria generated a minimum cost of $1.3 billion in the United States in 1992), the costs of increased hospitalization of patients with community acquired resistant bacteria, and a higher attributable mortality associated with infections caused by methicillin resistant Staphylococcus aureus (as compared to methicillin sensitive Staphylococcus aureus);13 and
Being aware of the agencies and organizations addressing this problem: the Centers for Disease Control and Prevention's strategy for addressing the antimicrobial resistance threat,14 the World Health Organization Executive Board's call for increased work against antimicrobial resistance,15 and the Food and Drug Administration's (FDA's) Advisory Committee on Antibiotic Resistance statement in October 1998, that "Microbial development of resistance to the presently available drug therapies is a public health issue of accelerating importance;"16 therefore
Äî 50% íåîáîñíîâàííûõ ïðèìåíåíèé àíòèáèîòèêîâ!!!

 çàêëþ÷åíèå äâà çàìå÷àíèÿ, êàê ðàç ñî ÑÏÈÄîì â ÑØÀ áîðþòñÿ äîâîëüíî ýôôåêòèâíî, ïî êðàéíåé ìåðå, òîëüêî çà 1997 ãîä ñìåðòíîñòü îò ÑÏÈÄà â ÑØÀ, ïî äàííûì àìåðèêàíñêîãî Íàöèîíàëüíîãî ñòàòèñòè÷åñêîãî öåíòðà çäîðîâüÿ óïàëà íà 47%, è ýòà áîëåçíü â ñïèñêå ñàìûõ ñòðàøíûõ ïåðåìåñòèëàñü ñ 6-ãî ìåñòà íà 14-å.
À âîò
ßòðîãåííûå áîëåçíè - çàáîëåâàíèÿ, ïðèîáðåòåííûå â ðåçóëüòàòå ìåäèöèíñêîãî ëå÷åíèÿ - òåïåðü ïðèçíàíû êàê îïàñíîñòü äëÿ çäîðîâüÿ ãëîáàëüíîãî ìàñøòàáà.
MEDLINE (êîìïüþòåðèçîâàííàÿ áàçà äàííûõ ìåäèöèíñêèõ èññëåäîâàíèé Íàöèîíàëüíîé Áèáëèîòåêè Ìåäèöèíû Ñîåäèíåííûõ Øòàòîâ (United States National Library of Medicine) âêëþ÷àåò ñâûøå 7000 ñòàòåé, îò÷åòîâ è íàó÷íî èññëåäîâàòåëüñêèõ ðàáîò ñ 1966 ãîäà, êîòîðûå ïîêàçûâàþò ñóùåñòâåííîå ÷èñëî ïàöèåíòîâ, ñòðàäàþùèõ ïðè÷èíåííûìè ëå÷åíèåì íàðóøåíèÿìè è ïîáî÷íûìè ëåêàðñòâåííûìè ðåàêöèÿìè.
…………………………………………………………………..
 ñâîåé ñòàòüå â Æóðíàëå Àìåðèêàíñêîé Ìåäèöèíñêîé Àññîöèàöèè (Journal of the American Medical Association), ä-ð Ëþñüåíà Ëèï èç Ãàðâàðäñêîé Øêîëû Îáùåñòâåííîãî Çäîðîâüÿ (Harvard School of Public Health), ïîäñ÷èòàëà, ÷òî 180000 òûñÿ÷ ÷åëîâåê óìèðàþò â ÑØÀ êàæäûé ãîä îò÷àñòè â ðåçóëüòàòå ÿòðîãåííûõ ïîðàæåíèé, ÷òî ýêâèâàëåíòíî òðåì àâèàêàòàñòðîôàì êàæäûå äâà äíÿ" (3).

 äðóãîì íîìåðå Æóðíàë Àìåðèêàíñêîé Ìåäèöèíñêîé Àññîöèàöèè óêàçûâàåò, ÷òî âðåä îò ìåäèöèíñêîãî ëå÷åíèÿ â ÑØÀ "çàòìåâàåò åæåãîäíóþ ñìåðòíîñòü â àâòîìîáèëüíûõ àâàðèÿõ â 45000 ÷åëîâåê è îáúÿñíÿåò áîëüøå ñìåðòåé, ÷åì âñå äðóãèå íåñ÷àñòíûå ñëó÷àè âìåñòå âçÿòûå" (4).

3. Journal of the American Medical Association. 1994; 272: 1851-1857.
4. Journal of the American Medical Association. 1995; 274: 29-34.

P.S. Åù¸ ðàç ïîâòîðþñü. ß íå ïðîòèâ ìåäèêàìåíòîçíîé òåðàïèè. Îíà áûëà, åñòü è åù¸ äîëãî áóäåò íåîáõîäèìà. Âîçðàæåíèÿ âûñêàçûâàþòñÿ ïðîòèâ îäíîáîêîñòè ðàçâèòèÿ ñîâðåìåííîé ìåäèöèíû, ïðè ÷åì íå ã. Çàéöåâûì (îò íåãî ìîæíî îòìàõíóòüñÿ), à ìíîãèìè àâòîðèòåòíûìè ñïåöèàëèñòàìè, êàê ó íàñ, òàê è çà ðóáåæîì. Ññûëêè íà ýòè ìíåíèÿ ÿ íåîäíîêðàòíî ïðèâîäèë.
Îòâåòèòü ñ öèòèðîâàíèåì
  #43  
Ñòàðûé 11.11.2002, 20:10
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,440
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,680 ðàç(à) çà 32,754 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âëàäèìèð ßêîâëåâè÷ , à ïî÷åìó ÍÅÎÁÎÑÍÎÂÀÍÍÎÅ ïðèìåíåíèå àíòèáèîòèêîâ Âû ðàññìàòðèâàåòå êàê ðåçóëüòàò èñïîëüçîâàíèÿ ÑÒÀÍÄÀÐÒΠëå÷åíèÿ ? Íåîáîñíîâàííîå - êàê ýêñïåðòû óçíàþò , ÷òî ëå÷åíèå áûëî íåîáîñíîâàííûì , ïî - ÂÀøåìó , è ñ êàêèì èç ñòàíäàðòîâ ëå÷åíèÿ( èëè îáñëåäîâàíèÿ ) êàêîãî çàáîëåâàíèÿ Âû êàòåãîðè÷åñêè íåñîãëàñû ?
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #44  
Ñòàðûé 11.11.2002, 21:44
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Ãàëèíà Àôàíàñüåâíà!
ß íå îáñóæäàþ, äà è íå ìîãó, åñòåñòâåííî, îáñóæäàòü êàêèå-ëèáî êîíêðåòíûå ðåêîìåíäàöèè.
Íî çàìåòüòå, â íàñòîÿùåå âðåìÿ, ïðàâèëüíàÿ òåðàïèÿ â ðàçëè÷íûõ ìåòîäè÷åñêèõ ðóêîâîäñòâàõ, ñòàòüÿõ, êîíôåðåíöèÿõ, â áåñåäàõ âðà÷åé äðóã ñ äðóãîì (íå ãîâîðÿ óæ î ìíîãî÷èñëåííûõ ïàìÿòêàõ ôàðì. ôèðì) ðàññìàòðèâàåòñÿ ñóãóáî, òîëüêî êàê ïðàâèëüíûé âûáîð ëåêàðñòâà.  òàêîé àòìîñôåðå ïðèâû÷íîñòè, ïîâñåäíåâíîñòè «òàáëåòîê» íåóäèâèòåëüíî, ÷òî äëÿ âðà÷åé åñòåñòâåííåé ïåðåäàòü ëåêàðñòâî, ÷åì íåäîäàòü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #45  
Ñòàðûé 12.11.2002, 01:15
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íî îò ïíåâìîíèè ñìåðòíîñòü âîçðîñëà èëè ñíèçèëàñü?
Âû ïîæàëóéñòà Âëàäèìèð ßêîâëåâè÷ äî÷èòûâàéòå ÷òî íàïèñàíî ìíîþ è òùåòåëüíåå ïåðåâîäèòå àíãë. òåêñò. Ñìåðòíîñòü òî âîçðîñëà, äà òîëüêî â ãðóïïå ñòàðøå 65 ëåò ïðåèìóùåñòâåííî. À íàèáîëåå çíà÷èìî ïðîäîëæèòåëüíîñòü æèçíè â ÑØÀ âîçðîñëà êàê ðàç â ïåðèîä îò 1980 äî 1995. Òàê óæ ñòàíäàðòû ïîñòàðàëèñü. Îïÿòü íå ïîíÿòíî?

Âû ïîïðîñèëè, òî÷íåå ïîòðåáîâàëè, ÷òîáû Âàì ïðåäîñòàâèë ññûëêó, è ãäå Âû îïÿòü îáíàðóæèëè ïðîèñêè ÑÌÈ?
Âû ÷åëîâåê íå ïîíèìàþùèé îáîáùåíèé è àëëåãîðèé. Íàâåðíîå ñëèøêîì ñåðúåçíî âîñïðèíèìàåòå êðèòèêó â ñâîé àäðåñ? Âîîáùå æå ÿ ïðåäïî÷èòàþ ïî âîçìîæíîñòè ÷èòàòü îðèãèíàëû, à íå ïåðåâîäû.

Åäèíñòâåííîå, ÷òî îòëè÷àåò ýòî âðåìÿ - óêëîí íà àáñîëþòíóþ «ñõåìèçàöèþ» ëå÷åíèÿ, ïîÿâëåíèå âñåâîçìîæíûõ «çîëîòûõ ñòàíäàðòîâ», íàïèñàííûõ ïðè àêòèâíîì ó÷àñòèè ôàðìèíäóñòðèè, è êàê ñëåäñòâèå, ðîñò ïðîèçâîäñòâà è óïîòðåáëåíèÿ ëåêàðñòâ. Ïðè÷åì, ïðè ñâîåé ïðèâåðæåííîñòè ê ìåäèêàìåíòàì, âðà÷è íå îñòàíàâëèâàþòñÿ íà äîñòèãíóòîì.
À èíòåðåñíî, êðîìå òîâ. Æóêîâñêîãî è åìó ïîäîáíûõ äåÿòåëåé, êòî íèáóäü ðàçäåëÿåò ýòó òî÷êó çðåíèÿ, íàïîìèíàþùóþ ìíå, ïðîñòèòå, ñèñòåìíûé áðåä, øïèîíîìàíñêóþ ñîöèàëèñòè÷åñêóþ ïàðàíîéþ è ò.ï. îáðàçöû âå÷íûõ ïîèñêîâ çëîñ÷àñòíûõ ïðîèñêîâ âðàãîâ? Âî âñÿêîì ñëó÷àå âî âñåõ öèòèðîâàííûõ âàìè ñòàòüÿõ ïîäîáíûõ âåùåé íå íàïèñàíî.

190 million daily doses of antibiotics are ordered in hospitals with twenty-five to forty-five percent being unnecessary Âû âîò ýòó ôðàçó â ñîñòîÿíèè íà ðóññêèé ïåðåâåñòè è âàâîä èç íåå ñäåëàòü? Çäåñü ãîâîðèòñÿ âåäü î íåíóæíîì íàçíà÷åíèè ÀÁ!!! À ÷òî íåíóæíîå íàçíà÷åíèå ïî îòíîøåíèþ ê ÷åìó îïðåäåëÿåòñÿ??? Ïðàâèëüíî, ê ñòàíäàðòàì. Îíè âåäü è ïèøóòñÿ íà îñíîâàíèè íåêèõ "ïðàâèëüíûõ" äàííûõ. À Âû äóìàëè çà÷åì? Âîò òóò äî ìåíÿ äîùëè ñëóõè. ÷òî ðîññèéñêèå óðîëîãè÷åñêèå ñòàíäàðòû ñîáèðàþòñÿ ïèñàòü äëÿ òîãî, ÷òîáû ñîãëàñíî èõ âñå ËÓ îñíàùàòü è ñíàáæàòü îïðåäåëåííûìè ìåäèêàìåíòàìè è îáîðóäîâàíèåì îò îïðåäåëåííûõ ôèðì. ÍÎ ÝÒÎ ÆÅ ÐÎÑÑÈß!!! ÇÄÅÑÜ ÏÐÎÑÒÎ ÂÎÐÓÞÒ!!! À Âû ñ Âàøèì ðîññèéñêèì êàéëîì õîòèòå ìåðèòü öèâèëèçîâàííóþ ðåàëüíîñòü. Ýòî íåâîçìîæíî. Ñúåçäèòå íà ñòàæèðîâêó ê èòàëüÿíñêèì òîâàðèùàì ïî ïàðòèè îçîíîòåðàïåâòîâ.

P.S. Òóê, òóê, Âëàäèìèð ßêîâëåâè÷.  ñòî ïåðâûé ðàç. Ãèïåðáàðè÷åñêàÿ îêñèãåíàöèÿ - ìåäèêàìåíòîçíûé ìåòîä? Íåò! Íî âåäü âõîäèò â ñòàíäàðòû ëå÷åíèÿ ÷åëîâå÷åñêèõ áîëÿ÷åê. Óäàðíîâîëíîâàÿ ëèòîòðèïñèÿ - ìåäèêàìåíòîçíûé ìåòîä? Íåò! È òî æå â ýòè æå íåíàâèñòíûå âàì ñòàíäàðòû ïîïàëà. Òîëüêî âîò îçîí÷èêó íå ñâåçëî, äà è èäåè âðîäå âàøèõ íè â ÷üè ìîçãè ïî÷åìó òî áîëüøå íå ïðèõîäÿò. Ðàçâå ÷òî àêàäåìèêó íåèçâåñòíî êàêîé àêàäåìèè òîâ. Æóêîâñêîìó è èæå ñ íèì.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 18:48.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.